Evaluating sustained adherence to ibrutinib in previously treated CLL - European Medical Journal

Evaluating sustained adherence to ibrutinib in previously treated CLL

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton’s tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukaemia (CLL) from the phase 3 RESONATE trial.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>